Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Abstract The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia. A single‐center, open‐label study evaluated the PKs of daridorexant in pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse
Format: article
Language:EN
Published: Wiley 2021
Subjects:
Online Access:https://doaj.org/article/fc8b4cfe396c4a1ebd06e4c57683c6a4
Tags: Add Tag
No Tags, Be the first to tag this record!